(MT Newswires) -- Novavax Inc. (NVAX) said there's substantial doubt about its ability to stay in business through next year, underscoring the depth of the drugmaker's struggle to develop and sell a Covid-19 vaccine. The stock plunged after hours. Bloomberg's Angelica Peebles reports.

Bloomberg videos